Book: Billion Dollar Lessons 💰 by Paul B. Carroll

“Read and learn about the costly mistakes of others; it could save you tremendous time and money.”

This thread will be updated as I read further.
1/ True Business Education?
2/ “Organizations involved in life-and-death situations—such as hospitals, airlines, and the military—routinely do after-action analyses that help them keep from repeating catastrophic errors.”

Investors should follow the same.
3/ “The extent of the failures was stunning. Since 1981, 423 U.S. companies with assets of more than $500 million filed for bankruptcy. Their combined assets at the time of their bankruptcy filings totaled more than $1.5T. Their combined annual revenue was ~ $830B.”
4/ “We found that failures often don’t stem from lack of execution. Nor are they due to timing or luck. What we found, instead, is that many of the really big failures stemmed from bad strategies.

Once launched, the strategies were doomed to fail.”
5/ Are we doomed to fail?
6/ Customers aren’t loyal to a company’s brand (more so in a price conscious country like 🇮🇳)
7/ What doesn’t cause failure?
8/ “As Alfred Hitch-cock said, the scariest villains aren’t the ones who arrive on camera wearing black hats and accompanied by eerie music; the scariest are those who seem like normal, even nice, people and only gradually reveal themselves to be evil at the core.”
9/ “Armies of bright young people go to business school so they can learn strategic frameworks, regression analysis, and other arcana. Yet most analysis goes to support a decision that’s already been made, rather than to see whether it’s really a good idea in the first place.”
10/ “Investment bankers (who get their fees anytime a company completes a transaction, regardless of whether it succeeds—and who get paid again when they’re hired to unwind transactions they proposed in the first place)”
11/ Aye.
12/ “Business isn’t physics. Business isn’t about finding the exact right answer, but rather is about avoiding the wrong answers and then executing as hard and as well as possible the answers that might be right.”
13/ Why should investors read this book?
14/ Deadly sin Number One: SYNERGY.
15/ Next time…
16/ Inorganic route to growth.
17/ Presume Failure.
18/ Press Releases are full of fiction.
19/ Explains why Zomato is closing down all it’s synergistic businesses:
20/ Much easier to build a PowerPoint Presentation & cash in than to speak the truth.
21/ Why it makes me suspicious when big conglomerates are buying start-ups like we buy groceries (once, every day)
22/ “When consulting firms do studies like, on how hard it is to achieve synergies, the suggestion usually is that there are ways to get those synergies if you just execute properly—by hiring that consulting firm.” 😂
23/ Partnership >>> Buyout.
24/ How to value a synergistic merger/acquisition?
25/ The two most dangerous words in Wall Street’s vocabulary: FINANCIAL ENGINEERING.
26/ 1st bad deed.. 2nd… 5th… Snowballs!
27/ Be careful of Gold wrapped 💩
28/ The reason behind the great financial crisis in 100 words or less 👇
29/ Salesmanship wins.
30/ “They basically jacked up their sales by lending more to people with bad credit,” one industry analyst observed. “It’s one of those retailing things that just gets repeated and repeated.”

Also, this 👇 (Spiegel)
31/ “The great pity is that they did not know how to take advantage of their advantages.”
32/ “In a survey of 743 U.S., European, & Asian CFOs, a third responded that if their companies were going to miss analyst expectations, they would use “discretion” to buff the numbers; 46 percent of the U.S. executives said they could influence earnings by at least 3 percent.”
33/ Too good to be true?
34/ better be cautious when the CEO appears on face of magazines, cited as “Most aggressive”
35/ Will it survive-

What if the company’s strategy is announced in Harvard business review? Onset of competitors.

What if a company goes through a decadal slowdown? Worst of Cashflows.
36/ “A small chance of distress or disgrace cannot, in our view, be offset by a large chance of extra returns.”
37/ Complex corporate structures are a red flag.
38/ “If the rabbit was running, we shot at it. It didn’t matter whether the rabbit had two legs, one leg or three ears. And a lot of the time it turned out to be a skunk.” ~An Executive of a company, aggressive on acquisitions.
39/ A story on ‘Purchasing Power’
40/ “In theory, a company should be able to raise prices as it grows in size and squeezes out the competition. But, sometimes, just enough competition remains and keeps a lid on prices, or customers are obstinate about not paying more, or something else goes wrong.”
41/ Growth Investor?
42/ The Kodak moment?

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with ᴀɴɪsʜ ᴍᴏᴏɴᴋᴀ

ᴀɴɪsʜ ᴍᴏᴏɴᴋᴀ Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AnishA_Moonka

13 Sep
Top 5 global pharma cos. (by rev)

J&J- $83B
Roche- $55B
Novartis- $49B
Merck- $48B
Pfizer- $42B

Top 5 Indian Pharma cos. (by rev)

Sun- $4.7B
Aurobindo- $3.3B
Cipla- $2.7B
Dr Reddys- $2.6B
Cadila- $2.1B

$1.6T market by FY25, Not investing in 🇮🇳's pharma growth story is a risk.
What makes us optimistic? $236B worth of innovator drugs patent expiry to happen in the next 4-5yrs.

Who are the most competitive players that will gobble up the opportunity? Indian Pharma cos.

Whether be it biosimilars or complex generics.

Src- Care Ratings
The costs of production in India is 50% cheaper than the developed markets

The cost of R&D is 1/8th the developed markets

The cost of clinical trials is 1/10th the developed markets.

+ Trained & specialized pharma workforce.
Read 7 tweets
9 Sep
All the companies in the Cement Fibre Products Industry have given huge returns in the past year 👇

Let's understand what drives the industry & the risks.

Hit the 'retweet' to help us educate more investors.

A Thread 🧵
1/ The Indian roofing industry is worth Rs 42,000 Crores and is expected to grow at the rate of 6-8% cagr.

So, What are the different options & what sets them apart?
2/ Among the pucca houses, less than half use RCC slabs; the rest utilize ready-to-use house roofing products (fiber cement roofing/ metal roofing).

Comparison between different options 👇

Now, this clears the superiority of Fiber Cement Sheets, let move further.
Read 19 tweets
2 Sep
Ami Organics IPO notes ⚗️

Supplies Raw materials (Intermediates) to API players (7% of revenues from Laurus Labs for example)

Hit the 'retweet' & help us educate more investors

A Thread 🧵👇
1/ Basics about the IPO.

Raising 200crs of Fresh Issue (& OFS of 370crs): will be used for repayment of debt & WC

MCap at 2200crs: EV/S of 6 & EV/EBITDA of 26 (stretched for an unknown company)

Promoters only hold 41% after the IPO
2/ An Pharma intermediates player that sells to API players focusing on high-growth therapeutics.

Caters to 150 customers (incl. Laurus, Cadila & MNC players, etc) | 50% exports
Read 12 tweets
2 Sep
Semiconductor shortages are creating some fantastic opportunities in the broader stock market; think FY24 & swing the bat.
On the contrary, the current supply crunch will help the OEMs to pass on the increased RM costs.

This will reflect in the bottom line & gross margins (OEMs have seen a 6-7% reduction from FY18) when this normalizes.
High uncertainty in the short term is the best friend of a long-term patient investor.

Look for companies that have high operating leverage play (including financial leverage), are not being talked about in the investment circles & where the promoters have everything to lose.
Read 4 tweets
24 Aug
"We are carrying Rs 27,936 crore of fixed-rate liabilities at 8.66%, largely legacy, and you can imagine the upsides when these are replaced by low-cost deposits." ~ V. Vaidyanathan, IDFC First Bank FY21 AR.
"We advise our product teams to design products in such way that it is meant to be sold to our 'near and dear' ones. We make products with transparent pricing and fees."
"We don’t pressurize our employees to 'somehow' sell high-margin products to meet fee targets. The list of our 'Customer First' features is long."
Read 14 tweets
3 Aug
Krsnna Diagnostics IPO notes: 'Let's do Good' ❓

Hit the 'retweet' & help us educate more investors

A thread 🧵👇

#IPOwithJST
1/ Basics about the IPO

Issue Dates: 4 - 6 August
Issue Size: ₹ 1,211 Crore (400crs Fresh Issue & 811crs OFS)
Mcap at the upper band: 2994crs
Price Band: ₹ 933 - 954
Retail Quota: 10%

Promoter stake to go from 32% to 27% post IPO.
2/ About the company.

Krsnaa Diagnostics provides technology-enabled services such as imaging (including radiology), pathology/clinical laboratory, and teleradiology

to public and private hospitals, medical colleges and community health centres across India.
Read 13 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(